🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseMASH prevalence in GLP-1 users — November 2025 Page 4

MASH prevalence in GLP-1 users — November 2025

tampaLisa73 Sun, Mar 9, 2025 at 3:50 AM 44 replies 2,251 viewsPage 4 of 9
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Mar 9, 2025 at 9:30 AM#16

Congrats SandraNC_45!! Keep going — you're doing incredible. 🎉

Last edited: Mar 9, 2025 at 11:30 AM
9 5NurseKim_ATL, paul_denver, TinaHashiRN and 6 others
Reply Quote Save Share Report
WendyG_ATL
Member
1,023
5,678
Apr 2024
Georgia
Mar 9, 2025 at 9:47 AM#17

tampaLisa73's experience with MASH prevalence in GLP-1 resonates deeply with mine. I went through almost the identical process — starting dose, titration timeline, side effects, everything.

The main difference: I had more GI issues initially. But the overall trajectory has been remarkably similar. Down 41 lbs in 6 months.

One thing I would add that tampaLisa73 did not mention: insurance coverage was a major hurdle.

Last edited: Mar 9, 2025 at 10:47 AM
7 21rachel_ABQ, traveltech_sara, AttorneyGrant and 4 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Mar 9, 2025 at 10:04 AM#18

Bookmarked 📌 The MASH prevalence in info in this thread is essential. Coming back to this for sure.

36 15DataDave, Dr.GutHealth, amsterdam_pete and 33 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Mar 9, 2025 at 10:21 AM#19

Clinical perspective on MASH prevalence in GLP-1 users November:

I have managed over 200 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that the medication works best as part of a comprehensive approach.

For this specific question, I would recommend: getting comprehensive baseline labs first.

2 23Dr.SurgeonPGH, rachel_ABQ
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Mar 9, 2025 at 10:38 AM#20

Subscribing to this thread. MASH prevalence in GLP-1 is exactly what I've been researching. 🙏

10 16LarryQC_SD, wanda_boise, NurseAsh_DET and 7 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register